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Abstract
Objectives—Pauci-immune glomerulonephritis is rare in African Americans (AA) and the
clinical presentation and treatment outcomes of vasculitis have not been well described.
Methods—We identified patients who were 2–92 years of age between 1983 and 2011 with a
diagnosis of biopsy-proven pauci-immune glomerulonephritis (GN) at any point during their
disease course. Comparing AA to Caucasian patients, we examined demographics, clinical
features at presentation, treatment and outcomes of relapse, end-stage renal disease (ESRD), and
death.
Results—Of the 672 patients, 75 were AA with the remainder being Caucasian. Compared to
Caucasians, disease onset in AA was at an earlier age (52 vs. 57 years, p = 0.05) and was more
often myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA) positive (71% vs.
54%, p = 0.01). AA patients had a shorter median time between onset of symptoms and biopsy
compared to Caucasians [median (IQR): 0.23 (0.00, 1.22) months vs. 0.66 (0.00, 3.62) months, p =
0.003]. Median [Interquartile range (IQR)] follow-up in months was 28 (5, 52) in AA and 26 (10,
55) in Caucasian patients. Median estimated glomerular filtration rate was similar at presentation
(21 vs. 22 ml/min/m2). Both groups had similar induction treatment regimens. There was less
favorable treatment response among AA compared to Caucasians for initial treatment resistance
(28% vs. 18%, p = 0.05) and complete remission (72% vs. 82%, p = 0.05). There were no
differences in the number of renal relapses or number of deaths between the 2groups. Overall, in
multivariable analyses controlling for age, race, ANCA type, and entry serum creatinine, there
were not differences by race in treatment response, renal relapse, ESRD, or death over the entire
time of follow-up. Conclusions: AA patients with pauci-immune GN are younger and more often
MPO-ANCA positive compared to Caucasians. Despite a shorter time to diagnosis for AA
patients, there were no differences compared to Caucasians in treatment response, ESRD, renal
relapse, or death rates by race over the entire duration of follow-up.
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Pauci-immune crescentic glomerulonephritis (GN) accounts for 80% of cases of rapidly
progressive glomerulonephritis [1–3]. The majority of cases of pauci-immune GN can be
attributed to primary systemic small vessel vasculitides including granulomatosis with
polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with
polyangiitis (eGPA). Some cases involve only the kidneys and can be categorized as renal-
limited vasculitis (RLV) [4]. Anti-neutrophil cytoplasmic antibody (ANCA) is a serologic
marker for pauci-immune glomerulonephritis. ANCA is present in 80–90% of patients with
pauci-immune GN and therefore these vasculitides are also called ANCA-associated
vasculitis (AAV) [5]. AAV occurs in older adults with no clear gender predilection and is
rare among African Americans (AA) [6]. Environmental factors and genetic susceptibility
are involved in inducing ANCA production. Recently, the HLA-DRB1*15 allele was found
to be associated with a higher risk of AAV in AA patients with proteinase 3 (PR3)-ANCA
compared to Caucasians [6]. There is evidence to suggest differences in disease expression
and outcomes among AA with other autoimmune diseases like lupus, rheumatoid arthritis,
and scleroderma [7].
This study aims to examine demographics, clinical features at presentation, and treatment,
and to correlate these variables with treatment response, rates of end-stage renal disease
(ESRD), time to first disease relapse, and death in AA patients compared to Caucasian
patients with biopsy-proven pauci-immune crescentic GN. The identification of race-related




The study population combined patients from a retrospective cohort from Johns Hopkins
Hospital (Maryland) and an inception cohort from the University of North Carolina Kidney
Center’s Glomerular Disease Collaborative Network (GDCN), which has previously been
described [8]. The study included patients with histologic confirmation of pauci-immune
glomerulonephritis by a kidney biopsy at any time point during the course of their vasculitis
from 1983 to 2011. “Pauci-immune” was defined as “the intensity of glomerular
immunoglobulin staining by direct immunofluorescence assay in renal sections being 0 to
1+, from a staining scale of 0 to 4+”. Patients were classified as GPA, MPA, or eGPA as
defined by the Chapel Hill Consensus Conference [9] and as RLV if they had pauci-immune
necrotizing and/or crescentic glomerulonephritis without any overt signs of systemic
vasculitis. The patients were followed up until ESRD, transplant, death, transfer to another
facility, or until the end of the follow-up period (December 31, 2011). An exclusion criterion
for this study was race besides AA or Caucasian. The study protocol was approved by the
Institutional Review Board at each institution.
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Clinical data—Data regarding patient demographics at the time of diagnosis, new vs.
established diagnosis, clinical features at presentation, occurrence of disease relapse, need
for renal replacement therapy at the time of diagnosis and at last follow-up, and details of
induction and maintenance immunosuppression were collected from review of medical
records. Kidney involvement was defined by a diagnostic renal biopsy or with the presence
of active urine sediment with or without renal insufficiency. Remission was defined as
stabilization or improvement in serum creatinine, resolution of hematuria, and absence of
extra-renal signs of vasculitis for 1 month [8]. Treatment resistance was defined as
progressive deterioration of renal function with the persistence of active urine sediment or
development of new or persistent signs of extra-renal vasculitis despite treatment with
immunosuppressive therapy for at least 1 month [8]. Relapse was defined as occurrence of
signs and symptoms of vasculitis in any organ requiring a change in immunosuppressive
therapy after achieving remission [6].
Laboratory data—Peak serum creatinine level at the time of diagnosis was recorded.
Renal function was measured using the 4-variable modification of diet in renal disease
(MDRD) formula [10]. ANCA testing was done by standard indirect immunofluorescence
assay on ethanol-fixed neutrophils for cytoplasmic ANCA (c-ANCA) and perinuclear
ANCA (p-ANCA). PR3 and myeloperoxidase (MPO) testing was done by direct enzyme-
linked immunosorbent assay (ELISA) with commercially available kits. An ANCA titer of
less than 10 was considered to be negative for c-ANCA and p-ANCA (reference range: 0–
10). PR3 and MPO levels of less than 20 units were considered negative (reference range:
0–20). If the testing for c-ANCA, p-ANCA, PR3 ELISA, and MPO ELISA was negative,
patients were labeled as having ANCA-negative vasculitis. Patients were categorized as
having cytoplasmic and/or proteinase 3-ANCA (thereafter referred to as PR3-ANCA) or
perinuclear and/or myeloperoxidase-ANCA (thereafter referred to as MPO-ANCA). p-
ANCA alone required negative anti-nuclear antibody test for the GDCN cohort but this was
not required for the Hopkins cohort.
Outcomes
The principal outcomes of interest in this cohort were complete remission, initial treatment
resistance, renal recovery after acute dialysis at diagnosis, time to first renal relapse, ESRD
(early or late), and death. ESRD was defined as the need for ongoing renal replacement
therapy in the form of dialysis or renal transplantation. Early ESRD was defined as the need
for renal replacement therapy within the first 3 months of diagnosis of pauci-immune GN,
and late ESRD was defined as the need for renal replacement therapy after the first 3 months
of diagnosis of pauci-immune GN.
Statistical analyses
All analyses were stratified based on race (AA vs. Caucasian) as determined from medical
records, with all other races excluded. Fisher’s exact test was used to evaluate differences by
race for categorical variables. Wilcoxon rank sum test was used to compare continuous
distributions between racial groups. Median and interquartile ranges (IQR) were reported for
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continuous measures with skewed distributions. For initial analysis of outcomes of interest,
we used a two-sample t test to compare AA and Caucasians. Multivariable analysis for
treatment resistance was done using logistic regression. Cox proportional hazards models
were evaluated to obtain multivariate hazards ratios and 95% confidence intervals for the
outcomes of relapse, ESRD, and death over the entire duration of follow-up. Evaluation for
relapse was limited to those who went into remission as a result of their initial treatment. We
controlled for the following predictor variables in multivariate models, with the goal of
understanding differences in race independent of these measures: age, sex, and ANCA type.
A p-value of 0.05 or less was considered to be significant. All analyses were done using
SAS software (version 9.3, SAS Institute, Cary, NC).
Results
Overall, 708 patients with biopsy-proven pauci-immune GN were identified (613 from the
GDCN and 95 from Johns Hopkins). Thirty-six patients with race other than African
American or Caucasian were excluded. Among the 672 with race identified, 75 (11%) were
AA with the remainder being Caucasian. Table 1 lists the demographics and baseline
characteristics by race. AA patients were younger at onset of disease with a mean age of 52
years compared to Caucasians with a mean age of 57 years (p = 0.05). ANCA negativity was
similar between AA and Caucasians (4% and 2%, respectively), and AA were more often
MPO-ANCA positive compared to Caucasians (71% vs. 54%, p = 0.01).
AA patients had a shorter median time between onset of symptoms and biopsy compared to
Caucasians [median (IQR): 0.23 (0.00, 1.22) months vs. 0.66 (0.00, 3.62) months, p =
0.003]. The frequencies of other organ system involvement were similar between the 2 racial
groups. Baseline renal function was similar between groups, with median estimated
glomerular filtration rate (eGFR) of 22 (IQR: 14, 45) ml/min/m2 in AA vs. 21 (IQR: 12, 38)
ml/min/m2 in Caucasians. The duration of follow-up was also similar in both groups, with a
median of 28 (IQR: 5, 52) months in AA and 26 (IQR: 10, 55) months in Caucasian patients.
The majority of patients in both groups were treated with the standard induction
immunosuppressive therapy of cyclophosphamide and oral corticosteroids (Table 1). A
minority of patients did not receive any immunosuppressive therapy for unclear reasons, and
4% of AA and 7% of Caucasians received other immunosuppressive therapy at induction
including mycophenolate mofetil, azathioprine, methotrexate, rituximab, and intravenous
immunoglobulin. There were no differences in the use of immunosuppressive therapy
between AA and Caucasian patients (Table 1). However, AA patients were more likely to
receive plasmapheresis compared to Caucasians (27% vs. 13%, p = 0.005).
Initial treatment resistance was more common among AA than Caucasians (28% vs. 18%,
respectively, p = 0.05; Table 2). However, controlling for differences in peak serum
creatinine at entry, age, sex, and ANCA specificity, there were no significant differences in
treatment resistance between the groups [OR = 1.49, CI = (0.65, 3.47), p = 0.35] (Table 3).
Although median eGFR at presentation was similar by race as described above, AA patients
required acute hemodialysis more often at the time of presentation, as compared to
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Caucasian patients (19% vs. 13%, p = 0.21). Among the 14 AA patients who required
dialysis at presentation, 8 (60%) recovered renal function; among 78 Caucasian patients
requiring dialysis at presentation, 60 (77%) recovered function (p = 0.18). AA patients were
more likely to reach ESRD in the first 3 months (8% vs. 3%, p = 0.04) in univariate analysis,
but this association disappeared in multivariable analysis controlling for age, gender, serum
creatinine at biopsy, and ANCA specificity [HR = 2.46, CI = (0.87, 6.92), p = 0.09]. At last
follow-up, 12 (16%) AA patients and 53 (9%) Caucasian patients had reached ESRD (p =
0.05; Fig.), but in multivariable analysis controlling for age, gender, MPO vs. PR3-ANCA,
and peak serum creatinine at entry, there was no difference by race, and age was the only
significant factor predictive of overall ESRD (Table 3).
Among the 50 AA who achieved remission, 18 (36%) experienced a disease relapse
compared to 227 (49%) of 464 Caucasians who experienced a disease relapse after
achieving remission. Renal relapse occurred in 12 AA patients (24%) compared to 137
(30%) Caucasians (p = 0.51). There were no differences in time to disease relapse or renal
relapse by race (p = 0.89 and 0.85, respectively). There were 14 (19%) deaths among AA
and 144 (24%) deaths among Caucasians during the follow-up period (p = 0.39). There were
no differences by race in multivariable models for time to relapse or death over the entire
follow-up controlling for age, gender, and ANCA specificity.
Discussion
This is the first descriptive study of an AA cohort of pauci-immune crescentic GN patients
describing the demographics, clinical features at presentation, and treatment response in
comparison to Caucasian patients with pauci-immune GN. Overall, 11% of our patients with
pauci-immune GN were AA. Our study shows that AA patients with pauci-immune GN are
younger at disease onset and are more often MPO-ANCA positive. There were no
differences in treatment response (rates of complete remission or initial treatment resistance)
between the groups. The rates of ESRD, relapse, and death in AA patients are similar to
Caucasian patients.
Pauci-immune GN and AAV are rare in the AA population and variable in all ethnicities [8].
There is growing evidence that GPA mainly affects people of European background [11]
and is rare in Japanese populations [12]. In contrast, MPA is seen with similar frequency to
GPA in the Caucasian population but occurs at twofold or higher rates in the Japanese
population [12]. Data from a multiracial population in France has indicated that AAV is
more common among Europeans than among residents of northern or sub-Saharan African
ancestry [13].
Previous reports on patients with pauci-immune GN have involved mostly Caucasian
patients [1,14–18]. Previous reports from the GDCN cohort have documented that the total
number of AA patients in their inception cohort of biopsy-proven vasculitis diagnosed
between 1985 and 2009 was 58 (11%) compared to 449 Caucasians [6]. In a recent study on
ANCA-associated GN in an elderly population (>80 years of age) out of New York, AA
comprised only 4.1% of the patient population [19]. The European Vasculitis Study Group
(EUVAS) vasculitis trials included 100% Caucasian patients [14,16,20] while the AA
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patients enrolled in the 2trials conducted in the United States ranged from 1.1% to 3% of
enrolled patients [17,18]. In contrast to these reports, AA patients in our study represented
11% of the entire cohort. This could be due to recent data that show differences in
demographics and outcome of AAV patients enrolled in clinical trials compared to those
followed in observational cohorts, with the trial patients being older, having worse renal
disease, and experiencing higher early mortality within the first year [21].
The mean age in our cohort is similar to those reported in other cohorts [6,15,18] and
younger compared to patients enrolled in some European cohorts and trials [14,16,22,23].
The onset of disease occurred earlier in AA in our cohort compared to Caucasians and is
similar to that in earlier reports from the GDCN [6]. Although both genders are usually
equally affected by AAV, there has been a preponderance among females in some studies
[14,15] similar to what was observed among AA in our study.
The distribution of disease phenotypes was not significantly different between the 2 groups,
although there was a slightly higher percent of patients with RLV and a lower percent of
patients with MPA in AA compared to Caucasians. However, AA were more likely to be
MPO-ANCA positive and this is in agreement with prior observations by the GDCN cohort
[6]. The lungs and upper respiratory tract were the most frequently involved extra-renal
organs among AA, and this was similar to Caucasians reported in other series [24]. The
median eGFR at diagnosis was similar between AA and Caucasians. The eGFR at diagnosis
is similar to that reported by Weidner et al. [25] and lower compared to what most vasculitis
clinical trials have reported [14,15,17,18]. The percentage of patients requiring hemodialysis
at presentation was 20% among AA. This is similar to those described among Caucasians in
other studies [25,26] and lower than those described in other cohorts [27,28].
The majority of our patients were treated with immunosuppressive therapy, and this is
similar to other cohort studies [29,30]. AA patients were more likely to receive
plasmapheresis. While this difference was likely due to a higher number of AA patients
requiring hemodialysis at presentation, this difference was not adjusted for the usual
indications of alveolar hemorrhage or dialysis-dependent renal failure for plasmapheresis in
this retrospective study. In addition, our cohort included patients since 1983 and
plasmapheresis was not routinely used in the management of AAV until the mid-1990s.
Overall, 72% of our AA patients treated with immunosuppression went into remission
compared to 82% of Caucasians. Similar rates of remission have been reported among
Caucasians by other groups [8,17,23,29,31]while higher remission rates are reported in some
vasculitis trials [14,15,18].
We anticipated higher treatment resistance in AA based on prior observations in AAV and
lupus nephritis. Previous observations by the GDCN cohort report female gender, AA race,
MPO-ANCA, and arteriosclerosis as predictors of treatment resistance [8]. In studies of
lupus nephritis, AA patients have inferior response to immunosuppressive treatment and
worse renal survival and patient survival compared to Caucasians [32]. Genetic factors
leading to differences in disease severity are felt to play a role in AA due to differences in
serologic and immunologic profiles among AA and Caucasians with lupus [32]. In our
study, after controlling for age, gender, serum creatinine, and ANCA specificity, there was
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no difference in proportion of patients with initial treatment resistance. However, we were
unable to look at histologic predictors in this retrospective study representing patients from 2
different institutions.
The rates of renal recovery in dialysis-dependent patients at presentation in our study are
higher compared to those reported by other groups [8,33–36]. The mean eGFR at 12 and 24
months in the dialysis-independent patients is similar to those reported in the
Cyclophosphamide Daily Oral Versus Pulsed (CYCLOPS) trial [20] and lower compared to
other cohorts [34]. The relapse rates observed in AA in our study are similar to those
reported by other cohorts [8,23,25] but higher compared to those reported in some clinical
trials [14,20] and low compared to other series [37–39].
Overall, 16% of AA reached ESRD compared to 9% of Caucasians in our study. The rates
of ESRD are similar to some studies [22] and lower compared to other reports [16,25]. In
our study, 19% of AA died compared to 24% of Caucasians over a median follow-up time of
28 (IQR: 10, 57) months. These death rates were lower than reported in some clinical trials
[14,18,20] and similar compared to other cohorts [16,22,23,25,34].
Our study has certain limitations. The clinical outcomes were not correlated with histologic
variables. Our study, like others, is limited by small patient numbers. Due to the high
prevalence of hypertensive renal disease in AA, we can speculate that AAV may be
underdiagnosed in AA. Despite differences in presentation, we are unable to show
differences in response to treatment and outcomes. Nevertheless, our study provides new
data for this rare but devastating condition in an AA cohort.
Conclusion
Pauci-immune glomerulonephritis is rare in AA patients. AA patients with vasculitis are
younger at disease onset and more often MPO-ANCA positive compared to Caucasians. The
potential benefit of the shorter time to diagnosis among AA did not result in better outcomes
with multivariable analyses revealing no differences in treatment response and nearly
equivalent rates of ESRD, renal relapse, and death rates by race over the entire time of
follow-up.
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Kaplan–Meier curve of kidney survival.
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Table 1
Comparison of demographics, disease phenotype, and induction therapy
Caucasian (N = 597, 89%) AA (N = 75, 11%) p-Valuea
Age (years) at diagnosis, mean ± SD 57 ± 18 52 ± 20 0.051
Females 268 (45%) 40 (53%) 0.18
ANCA typeb 0.0114
 Both 2 (0.34%) 0 (0%)
 PR3/c-ANCA 260 (44%) 19 (25%)
 MPO/p-ANCA 321 (54%) 53 (71%)
 ANCA neg. 13 (2%) 3 (4%)
Vasculitis type 0.17
 EGPA 2 (0.34%) 1 (1%)
 GPA 153 (26%) 19 (25%)
 Renal limited 122 (20%) 21 (28%)
 MPA 320 (54%) 34 (45%)
eGFR at diagnosis (ml/min)
 Median (IQR) 21 (12, 38) 22 (14, 45) 0.54
 Time from symptoms to renal biopsy (months)
 Median (IQR) 0.66 (0.00, 3.62) 0.23 (0.00, 1.22) 0.0028
Organs
 Lungb 307 (52%) 41 (55%) 0.63
 Upper respiratoryb 221 (37%) 22 (29%) 0.20
 Kidney 597 (100%) 75 (100%)
Induction with plasmapheresis b 78 (13%) 20 (27%) 0.0047
Induction therapy 0.48
 Prednisone alone 54 (9%) 8 (11%)
 Cyclophosphamide 486 (81%) 60 (80%)
 Othersc 40 (7%) 3 (4%)
 Not treated 17 (3%) 4 (5%)
Follow-up (months), median (IQR) 26 (10, 55) 28 (5, 52) 0.64
a
p-Values were calculated by Fisher exact test for categorical variables and Wilcoxon two samples for continuous variables.
b
There was 1 patient who had missing data for ANCA type and 1 patient who had missing data for lung involvement, 2 patients who had missing
data for upper respiratory tract involvement and 2 patients who had missing data for induction therapy.
c
Azathioprine, mycophenolate mofetil, methotrexate, rituximab, and intravenous immunoglobulin.
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Table 2
Outcomes by race: remission, relapse, ESRD, and death
Outcome parameters Caucasian (N = 597) AA (N = 75) p-Valuesa
Treatment responseb n = 563 n = 69 0.0504
 Remission 464 (82%) 50 (72%)
 Resistance 99 (18%) 19 (28%)
Acute dialysis at diagnosis 78 (13%) 14 (19%) 0.21
 ESKD ever 53 (9%) 12 (16%) 0.06
 Early ESKD (<3 months) 18 (3%) 6 (8%) 0.0412
 Median months to ESKD (IQR) 16 (0.3, 33) 3 (0.4, 22) 0.29
eGFR at 6 months (ml/min) (n, mean ± SD, median, and IQR) 303/597 22/75 0.55
38 ± 22 44 ± 30
34 (22, 49) 39 (20, 70)
eGFR at 1 year (ml/min) (n, mean ± SD, median, and IQR) 261/597 23/75 0.48
40 ± 23 48 ± 36
35 (23, 54) 41 (21, 72)
eGFR at 2 years (ml/min) (n, mean ± SD, median, and IQR) 195/597 14/95 0.0786
40 ± 24 51 ± 25
35 (23, 53) 45 (35, 71)
Renal relapse n (%)c n = 464 n = 50
 Median months to relapse (IQR) 137 (30%) 12 (24%) 0.51
18 (9, 38) 19 (8, 36) 0.85
 Deaths, n (%) 144 (24%) 14 (19%) 0.39
 Median months to death (IQR) 31 (6, 65) 36 (17, 64) 0.84
a
p-Values were calculated by Fisher exact test for categorical variables and Wilcoxon two samples for continuous variables.
b
Relapse data excludes n = 20 who were not treated, n = 3 who were death, and n = 17 who did not have follow-up information on treatment
response.
c
The patients who only had renal relapse and achieved remission.
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